Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women

K. Yaffe, J. Cauley, L. Sands and W. Browner
Department of Psychiatry, University of California, San Francisco, USA.

OBJECTIVE: To determine whether apolipoprotein E (Apo E) phenotype is associated with cognitive decline in community-dwelling nondemented elderly women. DESIGN: Prospective cohort study. SETTING: A university-affiliated clinic near Pittsburgh, Pa. PATIENTS: A total of 1750 nondemented community-dwelling women, aged 65 years and older, who were enrolled in the Study of Osteoporotic Fractures. MAIN OUTCOME MEASURES: The women completed a baseline interview and performed 3 cognitive tests: the modified Mini-Mental State Examination, Trials B, and Digit Symbol. Serum samples were obtained for Apo E typing. Baseline cognitive scores and repeated scores approximately 6 years after study enrollment were compared in women with and without Apo E epsilon 4. Cognitive decline, defined as the worst 10th percentile change scores, was assessed for each test and by phenotype group. RESULTS: After adjustment for age, education, presence of severe tremor, and depression, baseline scores did not differ by Apo E epsilon 4 status except for lower scores on Trails B in the homozygous epsilon 4 group (mean score, 159.7 compared with 127.7 for the heterozygous epsilon 4 group and 125.4 for the no epsilon 4 group; P = .01). However, repeated test performance on follow-up examination was worse on all tests in those women with 1 or more epsilon 4. Reduction on the modified Mini-Mental State Examination was 0% for no epsilon 4 allele, 1.9% for 1 epsilon 4 allele, and 3.7% for 2 epsilon 4 alleles (P < .001); reduction on Digit Symbol was 6.2% for no epsilon 4 allele, 9.0% for 1 epsilon 4 allele, and 17.5% for 2 epsilon 4 alleles (P = .04); and reduction on Trials B was 5.9% for no epsilon 4 allele, 25.0% for 1 epsilon 4 allele, and 10.9% for 2 epsilon 4 alleles (P = .002). Women with at least 1 epsilon 4 had an odds ratio of 1.6 (95% confidence interval, 1.1-2.3) of having cognitive decline during the study period. CONCLUSION: Apolipoprotein E epsilon 4 is associated with cognitive decline in community-dwelling nondemented women.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Methylenetetrahydrofolate Reductase C677T Polymorphism and Cognitive Function in Older Women
Elkins et al.
Am J Epidemiol 2007;166:672-678.
ABSTRACT | FULL TEXT  

Activation of estrogen receptor {alpha} increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo
Wang et al.
Proc. Natl. Acad. Sci. USA 2006;103:16983-16988.
ABSTRACT | FULL TEXT  

Apolipoprotein E {varepsilon}4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study
Lehmann et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:902-908.
ABSTRACT | FULL TEXT  

Apolipoprotein E {epsilon}4 and Change in Cognitive Functioning in Community-Dwelling Older Adults
Swan et al.
J Geriatr Psychiatry Neurol 2005;18:196-201.
ABSTRACT  

Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment
Devanand et al.
Arch Neurol 2005;62:975-980.
ABSTRACT | FULL TEXT  

Apolipoprotein {varepsilon}4 Allele and Problems With Orientation Are Associated With a Persistent Decline in Cognition in Community-Dwelling Elderly Persons
Wayne et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:375-379.
ABSTRACT | FULL TEXT  

Apolipoprotein E {varepsilon}4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults
Pomara et al.
Arch Gen Psychiatry 2005;62:209-216.
ABSTRACT | FULL TEXT  

APOE genotype and cognitive decline in a middle-aged cohort
Blair et al.
Neurology 2005;64:268-276.
ABSTRACT | FULL TEXT  

Apolipoprotein {epsilon}4 Allele Status, Depressive Symptoms, and Cognitive Decline in Middle-Aged and Elderly Persons Without Dementia
Lavretsky et al.
AJGP 2003;11:667-673.
ABSTRACT | FULL TEXT  

Normal Genetic Variation, Cognition, and Aging
Greenwood and Parasuraman
Behav Cogn Neurosci Rev 2003;2:278-306.
ABSTRACT  

Gender, cognitive decline, and risk of AD in older persons
Barnes et al.
Neurology 2003;60:1777-1781.
ABSTRACT | FULL TEXT  

The role of APOE-{epsilon}4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging
Bretsky et al.
Neurology 2003;60:1077-1081.
ABSTRACT | FULL TEXT  

Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions
Phillips and Bernhard
JNCI J Natl Cancer Inst 2003;95:190-197.
ABSTRACT | FULL TEXT  

The apolipoprotein E {varepsilon}2 allele and decline in episodic memory
Wilson et al.
J. Neurol. Neurosurg. Psychiatry 2002;73:672-677.
ABSTRACT | FULL TEXT  

The Apolipoprotein E {epsilon}4 Allele and Decline in Different Cognitive Systems During a 6-Year Period
Wilson et al.
Arch Neurol 2002;59:1154-1160.
ABSTRACT | FULL TEXT  

Clinically Significant Non-Major Depression: Old Concepts, New Insights
Lavretsky and Kumar
AJGP 2002;10:239-255.
ABSTRACT | FULL TEXT  

Memory complaints and APOE-{epsilon}4 accelerate cognitive decline in cognitively normal elderly
Dik et al.
Neurology 2001;57:2217-2222.
ABSTRACT | FULL TEXT  

Effect of apolipoprotein E genotype on hippocampal volume loss in aging healthy women
Cohen et al.
Neurology 2001;57:2223-2228.
ABSTRACT | FULL TEXT  

Apolipoprotein E Genotypes and the Incidence of Alzheimer's Disease among Persons Aged 75 Years and Older: Variation by Use of Antihypertensive Medication?
Guo et al.
Am J Epidemiol 2001;153:225-231.
ABSTRACT | FULL TEXT  

Is APOE-{epsilon}4 a risk factor for cognitive impairment in normal aging?
Small et al.
Neurology 2000;54:2082-2088.
ABSTRACT | FULL TEXT  

Estrogen use, APOE, and cognitive decline: Evidence of gene-environment interaction
Yaffe et al.
Neurology 2000;54:1949-1954.
ABSTRACT | FULL TEXT  

Cognitive Function and Apolipoprotein E in Very Old Adults: Findings From the Nun Study
Riley et al.
J. Gerontol. B Psychol. Sci. Soc. Sci. 2000;55:69S-75.
ABSTRACT | FULL TEXT  

Is Diabetes Associated With Cognitive Impairment and Cognitive Decline Among Older Women?
Gregg et al.
Arch Intern Med 2000;160:174-180.
ABSTRACT | FULL TEXT  

Current and the near future medications for Alzheimer's disease: What can we expect from them?
Shua-Haim and Ross
AM J ALZHEIMERS DIS OTHER DEMEN 1999;14:294-307.
 

Depressive Symptoms and Cognitive Decline in Nondemented Elderly Women: A Prospective Study
Yaffe et al.
Arch Gen Psychiatry 1999;56:425-430.
ABSTRACT | FULL TEXT  

Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: Increased susceptibility of females
Raber et al.
Proc. Natl. Acad. Sci. USA 1998;95:10914-10919.
ABSTRACT | FULL TEXT  

Estrogen Therapy in Postmenopausal Women: Effects on Cognitive Function and Dementia
Yaffe et al.
JAMA 1998;279:688-695.
ABSTRACT | FULL TEXT